Supplier
Elite Pain Management, LLC
Elite Pain Management, LLC was paid $3.53M by Medicaid between Jan 2018 and Dec 2024, across 36 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 22% of everything it billed.
33Billing provider infoELITE PAIN MANAGEMENT, LLC
SPRINGFIELD, MO 65804
SPRINGFIELD, MO 65804
33aNPI1609257773assigned 06/15/2015
33bProvider typeDurable Medical Equipment & Medical Supplies
28Total paid$3.53M
24GClaims67,881
24DCodes billed36
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Durable Medical Equipment & Medical Supplies providers in Missouri
Rank by total paid#14 of 252
Median peer was paid$17K
This provider vs. median206×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 17,338 | $994K | |
| 2019 | 12,474 | $655K | |
| 2020 | 8,451 | $384K | |
| 2021 | 8,141 | $345K | |
| 2022 | 10,115 | $461K | |
| 2023 | 8,915 | $525K | |
| 2024incomplete | 2,447 | $167K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 22% | 17,200 | 12,872 | $772K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 19% | 14,710 | 12,134 | $678K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 18% | 8,038 | 6,794 | $624K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 12% | 14,176 | 11,877 | $425K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 10% | 3,104 | 2,590 | $360K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 4.4% | 856 | 732 | $156K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 3.1% | 1,587 | 1,363 | $109K |
| 64493 | 1.9% | 1,149 | 941 | $68K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 1.6% | 432 | 374 | $57K |
| L0650 | Lumbar-sacral orthosis, sagittal-coronal control, with rigid anterior and posterior frame/panel(s), posterior extends from sacrococcygeal junction to t-9 vertebra, lateral strength provided by rigid lateral frame/panel(s), produces intracavitary pressure to reduce load on intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated, off-the-shelf | 1.5% | 182 | 72 | $52K |
| 64635 | 1.3% | 510 | 405 | $46K | |
| 27096 | 1.0% | 400 | 339 | $37K |
24 more codes
| 64494 | <1% | 1,088 | $33K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 467 | $24K |
| 64495 | <1% | 774 | $21K | |
| 64636 | <1% | 327 | $15K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 166 | $14K |
| 64450 | <1% | 194 | $10K | |
| 77002 | <1% | 288 | $10K | |
| L0648 | Lumbar-sacral orthosis, sagittal control, with rigid anterior and posterior panels, posterior extends from sacrococcygeal junction to t-9 vertebra, produces intracavitary pressure to reduce load on the intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated, off-the-shelf | <1% | 14 | $6K |
| 64640 | <1% | 348 | $4K | |
| 64451 | <1% | 54 | $3K | |
| 99205 | Prolong outpt/office vis | <1% | 33 | $2K |
| 62323 | <1% | 13 | $1K | |
| 96103 | <1% | 562 | $1K | |
| 64490 | <1% | 12 | $734.07 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 539 | $661.92 |
| 20553 | <1% | 17 | $441.72 | |
| 20552 | <1% | 19 | $370.66 | |
| 64492 | <1% | 12 | $369.53 | |
| 64491 | <1% | 12 | $365.03 | |
| 20610 | <1% | 14 | $296.34 | |
| 98967 | <1% | 51 | $250.97 | |
| 99422 | <1% | 14 | $224.83 | |
| 96127 | <1% | 410 | $83.37 | |
| 96146 | <1% | 109 | $15.38 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTONKIN, DAVID (DOCTOR)
| Provider | Location | Paid |
|---|---|---|
| Elite Pain Management, LLC | Little River, SC | $1.60M |
| Elite Pain Management, LLC | Las Vegas, NV | $966.30 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.